Novartis Takes Huntington's Path With SMA Therapy Branaplam
Priority Has Shifted After Rival Roche's Success
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
